-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
New Products
| Cat.No. | Product Name | Information | Added |
|---|---|---|---|
| E6510 | LOXO-435 | Jun 03 2026 | |
| E1852 | RLY-2608 | Jun 03 2026 | |
| E1309 | AP39 | AP39 is a triphenylphosphonium‑derivatised anethole dithiolethione and a mitochondria‑targeted hydrogen sulfide (H₂S) donor that increases intracellular, particularly mitochondrial, H₂S levels. AP39 also preserves mitochondrial DNA integrity under oxidative stress and protects against myocardial reperfusion injury in mice. | Jun 02 2026 |
| E6692 | QC6352 | Jun 01 2026 | |
| E6755 | Z4P | Jun 01 2026 | |
| E6645 | CellTracker Blue CMAC | May 31 2026 | |
| E1844 | STX-721 | May 31 2026 | |
| E4625 | Incyclinide | May 31 2026 | |
| E6752 | ADS032 | May 31 2026 | |
| F2577 | Von Hippel Lindau/VHL Antibody [A6D6] | May 27 2026 | |
| F9784 | ABCA1 Antibody [E4K4] | May 27 2026 | |
| A3177 | Inbakicept | May 26 2026 | |
| A3180 | Evorpacept | May 26 2026 | |
| A3181 | Socazolimab | May 26 2026 | |
| E4699 | Soquelitinib | Soquelitinib (CPI‑818) is an orally active and selective covalent (irreversible) inhibitor of interleukin‑2‑inducible T‑cell kinase (ITK). It modulates tumor immunity by reducing the expression of T‑cell exhaustion markers and can restore effector function in exhausted T cells. | May 24 2026 |
| E1851 | Succinyl phosphonate trisodium salt | Succinyl phosphonate trisodium salt, a trisodium salt of succinyl phosphonate, is a selective inhibitor of the α‑ketoglutarate dehydrogenase complex (KGDHC). By reducing KGDHC activity and succinyl‑CoA–dependent protein succinylation, it modulates mitochondrial metabolism and protects neurons from glutamate‑ and β‑amyloid‑induced injury. | May 24 2026 |
| E4761 | Osivelotor | Osivelotor (GBT‑601; GBT‑021601) is an orally effective small‑molecule allosteric modulator of deoxyhemoglobin S (HbS). It inhibits HbS polymerization and prevents erythrocyte sickling, and exhibits the potential to be used in the treatment and study of sickle cell disease (SCD). | May 24 2026 |
| E6803 | TRI-611 | TRI‑611 is a potent, brain‑penetrant molecular glue degrader of ALK fusion proteins that recruits CRBN to a distal degron, promoting polyubiquitination and degradation of wild‑type and TKI‑refractory ALK, and inducing tumor regressions in ALK‑positive NSCLC models. | May 21 2026 |
| E6583 | Atpenin A5 | Atpenin A5 is a potent and specific mitochondrial complex II inhibitor with an IC50 of ~10 nM. It also acts as an mKATP channel agonist and confers cardioprotection in models of ischemia–reperfusion injury. | May 21 2026 |
| E6833 | Glyphosate | Glyphosate is a non‑selective, systemic broad‑spectrum herbicide and a phosphonomethyl derivative of the amino acid glycine. It inhibits the enzyme 5‑enolpyruvylshikimate‑3‑phosphate synthase (EPSPS) in the shikimate pathway, thereby blocking synthesis of the aromatic amino acids phenylalanine, tyrosine, and tryptophan. | May 21 2026 |
| F8168 | HDAC7 Antibody [P6D17] | May 19 2026 | |
| E6757 | BBO-11818 | BBO‑11818 is an orally active and non‑covalent inhibitor of pan‑KRAS that binds both the active (GTP‑bound, “ON”) and inactive (GDP‑bound, “OFF”) forms of multiple oncogenic KRAS mutants, including KRAS G12D and G12V. It potently suppresses MAPK signaling and viability in KRAS‑driven cell lines, induces tumor regressions in KRAS‑mutant xenograft models. | May 19 2026 |
| E0875 | S26131 | S26131 (compound 5) is a potent, selective MT1 melatoninergic ligand that behaves as an antagonist at both MT1 and MT2 receptors, with Ki of 0.5 and 112 nM for MT1 and MT2, respectively. | May 19 2026 |
| E6710 | MKP10241 | MKP10241 is a potent, orally active agonist of GPR119 that elevates cAMP levels in a GPR119‑expressing cell line with an EC50 ≈ 3.7 nM. MKP10241 reduces blood glucose and HbA1c in acute and chronic diabetic mouse models and shows excellent preclinical efficacy in rodent models of obesity and MASH. | May 19 2026 |
| F5659 | MCT4/SLC16A3 Antibody [D23C24] | May 19 2026 | |
| F4739 | HDAC5 Antibody [B2J1] | May 19 2026 | |
| E5828 | GSK205 | GSK205 is a potent and selective antagonist of TRPV4 with an IC50 of 4.19 μM for inhibiting TRPV4‑mediated Ca²⁺ influx. | May 18 2026 |
| E6741 | SB-405483 | SB‑405483 is an allosteric cereblon (CRBN) ligand that cooperatively enhances the binding of orthosteric CRBN ligands (IMiDs) and potentiates degradation of CRBN neosubstrates, including CK1α, Wee1, and IKZF1/3. SB‑405483 stabilizes CRBN and reduces its autoubiquitination. | May 18 2026 |
| E6616 | CT-179 | CT‑179 is a brain‑penetrant, orally bioavailable inhibitor of OLIG2, which exhibits an IC50 of 1.25 μM for human OLIG2. It disrupts OLIG2 dimerization, phosphorylation, and DNA binding and alters tumor cell‑cycle kinetics, increasing differentiation and apoptosis. CT‑179 also prolongs survival in SHH‑MB PDX and GEM models and potentiates the effects of radiotherapy (RT) in vivo. | May 17 2026 |
| E0859 | Aminoxyacetic acid | Aminoxyacetic acid (AOAA) is an inhibitor of malate–aspartate shuttle (MAS) that effectively suppresses MAS activity in cells. It also induces both early‑ and late‑stage apoptosis of resting and LPS‑activated microglia and impairs their energy metabolism. | May 12 2026 |
| E6553 | BMS-986463 | BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader that significantly inhibits tumor growth and reduces phospho‑CDK2 levels in preclinical models. | May 12 2026 |
| E6771 | Bretisilocin | Bretisilocin (GM‑2505) is an agonist of 5‑HT2A receptor and 5‑HT releaser that is under development for the treatment of major depressive disorder (MDD). | May 12 2026 |
| E6677 | CATPB | CATPB is an antagonist of FFA2R that inhibits the transient rise in intracellular Ca²⁺ induced in neutrophils by acetate or the synthetic FFAR2 agonist Cmp1, thereby blocking downstream FFAR2‑dependent activation responses, including NADPH oxidase–derived superoxide production. | May 12 2026 |
| E6745 | Igermetostat | Igermetostat (XNW5004) is potent and selective, substrate‑competitive inhibitor of EZH2 that effectively targets both wild‑type and mutant EZH2, leading to marked reduction of H3K27me3, G1/S cell‑cycle arrest, and apoptosis in tumor cells. | May 10 2026 |
| E0862 | Leucylleucine methyl ester | Leucylleucine methyl ester is a lysosomotropic dipeptide that is taken up into leukocyte lysosomes via a dipeptide‑specific transport system and cleaved by the granule enzyme dipeptidyl peptidase I (cathepsin C) into hydrophobic oligomers, which disrupt intracellular membranes and selectively kill cytotoxic lymphocytes and other DPPI‑high cells, with species‑dependent sensitivity of B cells (murine B cells sensitive, human B cells largely resistant). | May 10 2026 |
| E6695 | 3α-Aminocholestane | 3-α-aminocholestane is a selective inhibitor of enzymatic activity of INPP5D (SHIP1), an enzyme with a role in controlling immune regulatory cell numbers in vivo, with an IC50 of ~2.5 μmol/l. | May 08 2026 |
| E6516 | L-Glutamine-13C5 | L-Glutamine-13C5 is a stable isotope-labeled form of the non-essential amino acid L-glutamine, where all five carbon atoms are replaced with the isotope^13C. It is primarily used as a tracer in mass spectrometry (LC-MS, GC-MS) or NMR for investigating metabolic pathways, protein synthesis, and cellular nutrient utilization, particularly in cancer research. | May 08 2026 |
| E6462 | IAMA-6 | IAMA‑6 (ARN23746) is a potent, selective, and orally bioavailable inhibitor of the NKCC1 cotransporter. It exhibits the potential to be primarily used in research to treat cognitive impairment in Down syndrome and autism by regulating intracellular chloride homeostasis. | May 07 2026 |
| E6718 | Polfurmetinib | Polfurmetinib(MEK-IN-6,PF-07799544,ARRY-134) (compound 69) is a potent and selective inhibitor of MEK that potently suppresses ERK1/2 phosphorylation at Thr202/Tyr204 in A375 melanoma cells with an IC50 of 2 nM. | May 06 2026 |
| E6737 | flizasertib | flizasertib (GDC-8264) is orally active, reversible, and selective inhibitor of receptor-interacting protein kinase 1 (RIP1), exhibiting Ki app values of 0.00071 μM against human RIP1 and 0.0013 μM against cynomolgus monkey RIP1. | May 06 2026 |
| E6733 | Adrixetinib TFA | Adrixetinib TFA(Q702 TFA) is an orally active, selective triple kinase inhibitor of CSF1R, Mer, and Axl receptors within the TAM (Tyro3/Axl/Mer), exhibiting Kd of 8.7 nM (CSF1R), 0.8 nM (Mer), and 0.3 nM (Axl). It also binds the ATP-binding pockets of these RTKs to block ligand-induced autophosphorylation, disrupting downstream PI3K/Akt and Gas6-mediated survival signaling while repolarizing tumor-associated macrophages from pro-tumorigenic M2 to anti-tumor M1 phenotypes. | May 06 2026 |
| E6732 | Mesutoclax | Mesutoclax (ICP-248) (Compound 5) is a potent, orally bioavailable, and selective inhibitor of BCL-2 with an IC50 of 1.54 nM demonstrating weak activity against BCL-XL with an IC50 > 1000 nM. | May 05 2026 |
| E5965 | BMS-986458 | BMS-986458 is a potent, highly selective, orally bioavailable CRL4 CRBN E3 ubiquitin ligase-dependent BCL6 ligand directed degrader, which exhibits the potential to treat B-cell non-Hodgkin Lymphoma. | May 05 2026 |
| E6729 | RGH-857 | RGH-857 (compound 51) is an orally active positive allosteric modulator (PAM) of the nicotinic α7 acetylcholine (α7 nACh) receptor with an EC50 of 34 nM for human α7 nAChR and demonstrating exceptional potency and efficacy in preclinical models of cognitive impairment. | May 05 2026 |
| E6713 | BLU-808(SAR449028) | BLU-808 (SAR449028) is a potent and selective inhibitor of wild‑type c‑KIT and potently inhibits c‑KIT–dependent phosphorylation and proliferation. It also exhibits therapeutic benefit to patients suffering from wild‑type c‑KIT–mediated mast cell disorders. | Apr 28 2026 |
| E6569 | MD-4251 | MD‑4251 is an orally active PROTAC degrader of MDM2. It potently degrades MDM2 in RS4;11 cells with a DC50 of 0.2 nM and activates p53. | Apr 28 2026 |
| E0865 | DFHBI-1T | DFHBI‑1T is a membrane‑permeable, non‑toxic fluorogenic probe that acts as a ‘light‑up’ sensor for RNA imaging in live cells. It specifically binds to RNA aptamers such as Broccoli, Spinach, and Spinach2, yielding strong green fluorescence with high signal‑to‑noise ratios. | Apr 28 2026 |
| E6494 | ATR-258 | ATR‑258 (Compound 15) is a specific agonist of GRK‑biased β2‑adrenergic receptor (β2AR) with a pEC50 of 6.87 that increases glucose uptake with low cAMP generation. | Apr 27 2026 |
| E6773 | Olorofim(F901318) | Olorofim (F901318) is a reversible inhibitor of dihydroorotate dehydrogenase (DHODH), an oxidoreductase that catalyzes the fourth step in the de novo synthesis of pyrimidines. It exhibits potential for the treatment of invasive mold infections and thermally dimorphic fungi that are refractory to or resistant to clinically available antifungals. | Apr 26 2026 |
| E6776 | AP-503 | AP‑503 is a selective agonist of GPR133/ADGRD1 with an EC50 of 1.21 nM. It exhibits the potential to be used in research on the prevention of muscle‑related diseases and vestibular dysfunction. | Apr 26 2026 |
| E6582 | LysoTracker Red(LysoTracker Red DND-99) | LysoTracker Red (LysoTracker Red DND-99) is an acidotropic, red-fluorescent probe (Ex/Em 577/590 nm) that selectively stains lysosomes and late endosomes in live cells. As a hydrophobic weak base, it freely diffuses across membranes at neutral pH (~7.4), becomes protonated in acidic compartments (pH 4.5-6.0), and traps via charge retention, preventing efflux for high-contrast imaging. | Apr 23 2026 |
| E5849 | KT-253 | KT-253 (Seldegamadlin) is a potent, selective heterobifunctional MDM2 degrader with a DC50 of 0.4 nM and p53 stabilizer. It also exhibits antitumor activity across p53 wild-type hematologic and solid tumors. | Apr 23 2026 |
| E6528 | BBT-176 | BBT-176 is a first-in-class reversible fourth-generation EGFR TKI with potent activity against osimertinib-resistant mutations with an IC50 of 49 nM (Del19/T790M/C797S), 202 nM (L858R/T790M/C797S), 42 nM (Del19/C797S), and 183 nM (L858R/C797S) in Ba/F3 cells. | Apr 21 2026 |
| E6738 | BCFTP | BCFTP is a potent, orally active, selective positive allosteric modulator (PAM) of human MrgprX1 that enhances endogenous ligand signaling to inhibit spinal C-fibre nociceptive transmission, thereby relieving heat hyperalgesia and spontaneous pain in neuropathic models without itch or tolerance. | Apr 21 2026 |
| E6663 | DDO-02267 | DDO‑02267 is a selective, lysine‑targeting covalent inhibitor of ALKBH5, with an IC50 of 0.49 μM. DDO‑02267 increases m⁶A levels and targets the ALKBH5–AXL signaling axis in AML cells. It exhibits the potential to serve as a chemical probe for investigating the biological function of the mRNA demethylase ALKBH5. | Apr 21 2026 |
| A2179 | Anti-Mouse CD41-Invivo | Anti-Mouse CD41-Invivo specifically binds to CD41, which is also known as glycoprotein IIb (gpIIb, GP IIb), Integrin α IIb chain, or Integrin alpha 2b. CD41 is a transmembrane glycoprotein that is encoded by Itga2b. CD41 associates with Integrin β3 chain (gpIIIa or CD61) to form the gpIIb/IIIa (CD41/CD61) complex. | Apr 20 2026 |
| E1270 | Afimetoran( BMS-986256) | Afimetoran (BMS-986256) is an orally active and selective antagonist of TLR7/8 that potently inhibits NF-κB activation and reverses TLR7-mediated steroid resistance in pDCs. | Apr 19 2026 |
| E0874 | Ulotaront hydrochloride | Ulotaront hydrochloride (SEP-363856 hydrochloride) is an orally active, CNS-penetrant psychotropic agent that acts as an agonist of the trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor. It acts as an antipsychotic and used for the treatment of schizophrenia. | Apr 19 2026 |
| E0873 | Niacin hydrochloride | Niacin hydrochloride (Nicotinic acid; Vitamin B3) is a direct and noncompetitive inhibitor of hepatocyte diacylglycerol acyltransferase–2(DGAT2), a key enzyme for TG synthesis, which results in accelerated intracellular hepatic apo B degradation and the decreased secretion of VLDL and LDL particles. | Apr 19 2026 |
| E6631 | Oxamic acid | Oxamic acid (Oxamate) is a classical inhibitor of lactate dehydrogenase‑A (LDH‑A) that competitively blocks the conversion of pyruvate to lactate. It also induces G2/M arrest and apoptosis, and increases radiosensitivity in nasopharyngeal carcinoma cells. | Apr 16 2026 |
| E6711 | ACI-19626 | ACI‑19626 (TDP‑43‑IN‑2) is a first‑in‑class, small‑molecule PET tracer that specifically binds to pathological TDP‑43 aggregates, which are key drivers of neurodegeneration in diseases such as ALS, FTD, and LATE. | Apr 16 2026 |
| F5646 | MLANA/MART-1 Antibody [D21A21] | Apr 15 2026 | |
| F7381 | ABCA7 Antibody [A11M15] | Apr 15 2026 | |
| F7735 | SirT4 Antibody [C24N9] | Apr 15 2026 | |
| F2359 | Phospho-GSK3β (Y216)/GSK3α (Y279) Antibody [F22P22] | Apr 15 2026 | |
| F4079 | Fas Antibody [C6C4] | Apr 15 2026 | |
| F8456 | ORC2 Antibody [P19N22] | Apr 15 2026 | |
| E6682 | CT-996(RO7795081，RG6652） | CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity. | Apr 14 2026 |
| E0863 | Talfirastide acetate | Talfirastide acetate (TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate) is an endogenous heptapeptide of the renin–angiotensin system (RAS) with a cardioprotective role due to its anti‑inflammatory and anti‑fibrotic activities in cardiac cells. It inhibits purified canine ACE activity with an IC50 of 0.65 μM and also acts as a local synergistic modulator of kinin‑induced vasodilation by inhibiting ACE and promoting nitric oxide release. | Apr 14 2026 |
| E6787 | Rineterkib hydrochloride | Rineterkib hydrochloride is an orally active, potent inhibitor of RAF and ERK1/2, exhibiting preclinical activity in multiple MAPK-activated cancer cell lines and xenograft models. | Apr 14 2026 |
| E6679 | PhIP | PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is a carcinogenic heterocyclic aromatic amine often generated in thermal processing of food. It induces DNA damage via CYP1A2 activation to hydroxylated metabolites forming C8-dG adducts and mutations. It also binds ERα to drive estrogenic signaling independent of genotoxicity, promoting epigenetic changes in MCF-7 breast cells akin to 17-β-estradiol, contributing to tissue-specific carcinogenesis in breast, colon, and prostate. | Apr 13 2026 |
| E0866 | Glycerophosphoric acid | Glycerophosphoric acid is a naturally occurring compound and an a‑site substrate analogue that, when bound to the a‑site, strongly inhibits the reaction of indole and nucleophilic indole analogues with E(A‑A). It also serves as a structural precursor of glycerophospholipids in cell membranes, contributing to membrane organization, fluidity, and transport regulation. | Apr 12 2026 |
| F4153 | Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] | Apr 09 2026 | |
| F1108 | RSK1 p90 Antibody [K1J12] | RSK1,RSK1 p90 | Apr 09 2026 |
| F4981 | HDAC11 Antibody [H19H1] | Apr 09 2026 | |
| F4999 | METTL14 Antibody [A8N22] | Apr 09 2026 | |
| E6546 | PF-07899895 | PF-07899895 (Compound 34) is an inhibitor of SIK, with an IC50 of 1.2 nM, 0.9 nM, and 1.8 nM for SIK1, SIK2, and SIK3, respectively. It also modulates the anti-inflammatory cytokine IL-10 in immune cells and exhibits potential applicable research related to inflammatory diseases. | Apr 08 2026 |
| E6742 | Z218484536 | Z218484536 is a selective and brain-penetrant inhibitor of phosphoserine phosphatase (PSPH) that binds to PSPH with a Kd of approximately 0.23 μM. | Apr 08 2026 |
| E0858 | Lavofloxacin lactate | Lavofloxacin lactate, the lactate salt of levofloxacin, is a fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to double-strand DNA breaks and bacterial cell death. | Apr 08 2026 |
| E1034 | PKH26 | PKH26 is a red fluorescent lipophilic dye (Ex/Em = 551/567 nm) that stably integrates into the lipid bilayer of cell membranes via its long aliphatic hydrocarbon tails, enabling long-term tracking without significant cytotoxicity or transfer between cells. | Apr 08 2026 |
| E6660 | FMC-376 | FMC-376 is a selective and irreversible dual inhibitor of both the ON and OFF states of KRASG12C. It binds covalently to the mutant cysteine at position 12 in KRAS G12C and directly blocks both the ON and OFF conformations of the mutant KRAS protein, leading to a complete and durable blockade of downstream signaling. FMC‑376 exhibits robust anti‑tumor activity in vivo. | Apr 08 2026 |
| E5864 | EG01377 Dihydrochloride | EG01377 dihydrochloride is a potent, bioavailable, and selective inhibitor of neuropilin‑1 (NRP1), with a Kd of 1.32 μM and IC50 609 nM for both NRP1‑a1 and NRP1‑b1. It also exhibits antiangiogenic, antimigratory, and antitumor effects in vitro. | Apr 08 2026 |
| E1577 | AZD4747 | AZD4747 is a selective, blood‑brain barrier‑permeable inhibitor of mutant GTPase KRASG12C, with the potential to treat KRAS^G12C‑positive tumors, including central nervous system (CNS) metastases. | Apr 08 2026 |
| S7151 | Garcinol | Garcinol is a polyisoprenylated benzophenone compound isolated from the fruit rind of Garcinia indica. It acts as a potent natural inhibitor of histone acetyltransferases (HATs), including p300 and PCAF, with IC50 of ~7 μM and 5 μM, respectively. It also exhibits anti-cholinesterase activity against AChE and BChE with an IC50 of 0.66 μM and 7.39 μM, respectively. | Apr 08 2026 |
| E6681 | Tinlarebant | Tinlarebant (LBS-008; BPN-14967) is an oral, non‑retinoid antagonist of RBP4, which exhibits potential to treat Stargardt disease and advanced dry age‑related macular degeneration. | Apr 08 2026 |
| P1254 | Rusfertide(PTG-300) | Rusfertide (PTG-300) is a hepcidin mimetic that targets ferroportin, inducing its internalization and degradation to block cellular iron export into the blood. By limiting transferrin saturation (TSAT), it reduces systemic labile iron toxicity and prevents organ iron deposition. Rusfertide exhibits the potential treatment for Hereditary Hemochromatosis and hemoglobinopathies like beta-thalassemia and also helps to improve anemia by promoting more effective erythropoiesis. | Apr 06 2026 |
| E6700 | G-6599 | G-6599 is a potent monovalent degrader of SMARCA2/SMARCA4 that covalently binds a cysteine on E3 ligase FBXO22, forming a ternary complex for ubiquitin-proteasome degradation. It exhibits potential research applications in androgen-dependent prostate cancer and SMARCA4-mutant non-small cell lung cancer. | Apr 06 2026 |
| E6476 | SBI-810 hydrochloride | SBI‑810 hydrochloride is a β‑arrestin–biased, functionally selective allosteric modulator of neurotensin receptor 1 (NTSR1) that alters NTSR1‑mediated G protein signaling in a G protein–specific manner when the endogenous ligand neurotensin (NT) is present, fully antagonizing NT‑induced Gq activation, partially antagonizing Gi1 activation, and remaining permissive toward NTSR1‑mediated activation of GoA and G12. | Mar 30 2026 |
| E5769 | MY-1B | MY‑1B is a covalent inhibitor of the RNA methyltransferase NSUN2, with an IC50 of 1.3 μM. MY‑1B stereoselectively targets the active‑site cysteine residue C271 of NSUN2 and can be used to probe the function of NSUN2 in RNA methylation‑related processes. | Mar 29 2026 |
| S9814 | BMS-986202 | BMS‑986202 is a potent, selective and orally active inhibitor of TYK2 that binds to the TYK2 pseudokinase domain (JH2) with an IC50 of 0.19 nM and a Ki of 0.02 nM. | Mar 24 2026 |
| E1584 | CCR6 inhibitor 1 | CCR6 inhibitor-1 is a potent and selective inhibitor of CCR6 with IC50 of 0.45 nM and 6 nM for monkey and human CCR6, respectively. It potently inhibits human B-cell migration and ERK phosphorylation, exhibiting potential as a treatment for autoimmune diseases. | Mar 24 2026 |
| E4769 | Aleniglipron (GSBR-1290) | Aleniglipron (GSBR‑1290) is a potent, orally available agonist of GLP‑1R that selectively activates the Gαs–cAMP signaling pathway without detectable β‑arrestin recruitment. | Mar 24 2026 |
| E1097 | Famitinib (SHR1020) | Famitinib (SHR1020), an orally active inhibitor of multi‑targeted kinase, which inhibits the activity of c‑Kit, VEGFR‑2, and PDGFRβ with IC50 of 2.3 nM, 4.7 nM, and 6.6 nM, respectively. | Mar 23 2026 |
| E6693 | PKUMDL-WQ-2101 | PKUMDL‑WQ‑2101 is a non‑NAD⁺‑competing allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 34.8 μM. It exhibits antitumor activity, selectively inhibits de novo serine synthesis in cancer cells, and reduces tumor growth in vivo. | Mar 23 2026 |
| P1273 | Ecnoglutide（XW003） | Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity. | Mar 23 2026 |
| E6703 | MLT-985 | MLT‑985 is a selective allosteric and orally active inhibitor of MALT1 with an IC50 of 3 nM. It inhibits MALT1‑dependent signaling in ABC‑DLBCL models and reduces cell growth and aberrant CARD11/BCL10/MALT1‑complex activity in vitro. | Mar 23 2026 |
| E1475 | CFT1946 (Tagarafdeg) | CFT1946 (Tagarafdeg) is an orally bioavailable, CRBN‑based bifunctional degradation‑activating compound (BiDAC) that selectively targets mutant BRAFV600E for ubiquitin–proteasome–mediated degradation, with a DC50 of 14 nM in A375 melanoma cells. | Mar 23 2026 |
| E6751 | Sodium iodoacetate(Iodoacetic acid sodium salt) | Sodium iodoacetate(Iodoacetic acid sodium salt) is a specific, covalent inhibitor of glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) that blocks glycolytic flux by alkylating the catalytic cysteine residue in the active site, thereby exerting glycolysis‑inhibitory activity in cells and tissues. It also induces osteoarthritis‑like joint degeneration and related pain models in experimental animals. | Mar 19 2026 |
| E6756 | MOCAc-PLGL(Dpa)AR | MOCAc-PLGL(Dpa)AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) is a FRET-based fluorescent peptide substrate for MMPs including MMP-7 (matrilysin), MMP-2, and MMP-9, where the MOCAc fluorophore is quenched by Dpa until cleavage at the Gly-Leu bond produces >10-fold fluorescence increase for activity assays. | Mar 19 2026 |
| E6456 | PF-07248144(Prifetrastat) | PF‑07248144 (Prifetrastat) is a potent and selective catalytic inhibitor of KAT6A and KAT6B that exhibits durable antitumor activity and the potential to treat metastatic breast cancer. | Mar 16 2026 |
| F0806 | Phospho-VEGF Receptor 2 (Tyr1059) Antibody [J6L3] | Mar 12 2026 | |
| F3541 | Phospho-Akt (Thr308) Antibody [F21G22] | AKT (phospho T308),AKT1 (phospho T308),pan-AKT (phospho T308),Phospho-Akt (Thr308) | Mar 12 2026 |
| F0653 | Phospho-VEGF Receptor 2 (Tyr951) Antibody [F15G14] | Phospho-VEGF Receptor 2 (Tyr951),VEGF Receptor 2 (phospho Y951) | Mar 12 2026 |
| F2677 | β Actin Antibody [H22G2] | ACTB,beta Actin,beta Actin Loading Control,beta-Actin,β-Actin | Mar 12 2026 |
| F4964 | Phospho-RIP (Ser161) Antibody [A1A2] | Mar 12 2026 | |
| F4004 | ATF1 Antibody [H17A19] | Mar 12 2026 | |
| F3361 | 6X His tag Antibody [G4E22] | 6X His tag,6XHIS,6x-His Tag,His-Tag,polyHistidine | Mar 12 2026 |
| E5879 | Elinzanetant | Elinzanetant (NT-814; BAY3427080) is a nonhormonal dual antagonist of NK1/NK3 receptor that reduces GnRH pulsatility by blocking neurokinin B (NK3) and substance P (NK1) effects on the reproductive axis in KNDy neurons. | Mar 12 2026 |
| E1593 | Camlipixant | Camlipixant (BLU-5937) is a potent, selective, non-competitive antagonist that target P2X3 homotrimeric receptor, with an IC50 of 25 nM for hP2X3 homotrimeric form. | Mar 12 2026 |
| E6702 | Opitor-0 | Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase), that regulates cristae remodeling and cytochrome c release, with an IC50 of 3 μM. | Mar 10 2026 |
| E8328 | Ro24-7429 | Ro24-7429 is a benzodiazepine derivative that acts as a potent, orally active antagonist of HIV-1's Tat transactivator protein, disrupting viral replication by inhibiting Tat-mediated transactivation of the HIV-1 long terminal repeat (LTR) promoter. It also inhibits RUNX1 (runt-related transcription factor 1), contributing to antifibrotic effects by reducing fibrosis markers in models like bleomycin-induced pulmonary fibrosis, alongside anti-inflammatory properties. | Mar 10 2026 |
| P1259 | Cagrilintide | Cagrilintide is a long-acting acylated amylin analogue functioning as a nonselective agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). Its dual action promotes satiety, slows gastric emptying, and reduces food intake through brain-mediated pathways with the potential to treat obesity. | Mar 10 2026 |
| E4671 | ML334 | ML334 (LH601A) is a potent, cell-permeable activator of NRF2 that disrupts the Keap1-NRF2 protein-protein interaction by binding the Keap1 Kelch domain with a Kd of 1 μM, promoting NRF2 nuclear translocation and antioxidant gene expression. | Mar 08 2026 |
| E6698 | STL1267 | STL1267 is a potent agonist of REV-ERB, with Ki of 0.16 µM for REV-ERBα that crosses the blood-brain barrier, enhancing NCoR corepressor recruitment to repress circadian and metabolic genes. | Mar 08 2026 |
| E6697 | PACMA 31 | PACMA 31 is an irreversible, orally active inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. It covalently binds PDI's active-site cysteines, inhibiting reductase/isomerase activity in a dose- and time-dependent manner per insulin aggregation assays. | Mar 01 2026 |
| E6661 | Ontunisertib | Ontunisertib (AGMB-129) is an oral, GI-restricted small molecule inhibitor of ALK5 (TGFβR1), exhibiting the potential to treat fibrostenosing Crohn’s disease (FSCD). It potently blocks pro-fibrotic TGFβ signaling locally in the GI tract via high first-pass metabolism. | Mar 01 2026 |
| E6659 | TYRA-200 | TYRA-200 is an orally bioavailable inhibitor of FGFR1/2/3 that exhibits potential to address clinically observed acquired resistance alterations in FGFR2, such as molecular brake and gatekeeper mutations. | Mar 01 2026 |
| F3556 | Phospho-FoxO1 (T24)/FoxO3a (T32) Antibody [M8K9] | Feb 28 2026 | |
| F0728 | FGFR3 Antibody [G21B24] | FGF Receptor 3,FGFR3,FGFR-3 | Feb 28 2026 |
| F1608 | Cleaved PARP1 Antibody [K10A21] | Feb 28 2026 | |
| F2463 | FADD Antibody [P17H10] | Feb 28 2026 | |
| F5322 | BRCC36 Antibody [M5D3] | Feb 28 2026 | |
| F7401 | SMARCD3/BAF60C Antibody [C13A4] | Feb 28 2026 | |
| F0346 | Phospho-PERK (Thr980) Antibody [E16F3] | Feb 28 2026 | |
| F3023 | IL-6 Antibody [F4K18] | IL-6 | Feb 28 2026 |
| F3061 | IL-1β Antibody [J24M1] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F2632 | BRCA1 Antibody [N12F20] | BRCA1 | Feb 28 2026 |
| F3067 | IL-1β Antibody [H12N7] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F3557 | Phospho-EGF Receptor (Tyr1045) Antibody [F16D14] | Feb 28 2026 | |
| F3443 | Phospho-p130 (Ser672) Antibody [E21C6] | Feb 28 2026 | |
| F4019 | SIRT7 Antibody [J3K9] | Feb 28 2026 | |
| F4814 | SOX10 Antibody [E22E2] | Feb 28 2026 | |
| F4857 | Apolipoprotein E Antibody [L10K14] | Feb 28 2026 | |
| F4146 | Phospho-Stat5 (Tyr694) Antibody [L6J15] | Feb 28 2026 | |
| F3968 | Phospho-EGFR (Tyr1101) Antibody [A24A1] | Feb 28 2026 | |
| E4770 | Jedi2 | Jedi2 is an activator of the Piezo1 channel that binds to mouse Piezo1 protein with a Kd of 2770 μM. | Feb 27 2026 |
| E6712 | PYCR1-IN-1 | PYCR1-IN-1 (compound 4) is an inhibitor of pyrroline-5-carboxylate reductase 1 (PYCR1) with an IC50 of 8.8 µM. It significantly reduce the levels of proline within a breast cancer cell line and exhibits anti-cell proliferation effect. | Feb 26 2026 |
| E6708 | HQ461 | HQ461 is a molecular glue degrader that promotes CDK12-DDB1-CUL4-RBX1 interaction, causing polyubiquitination and degradation of Cyclin K (CCNK). HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death. | Feb 26 2026 |
| E6637 | YCT529 | YCT-529 is a selective antagonist of retinoic acid receptor alpha (RARα) developed as a pyrrole-linked analog that potently inhibits RARα with an IC50 of 1.2 nM and greater than 300-fold selectivity over RARβ and RARγ. It also serves as oral non-hormonal male contraceptive effectively reduces sperm counts in mice and non-human primates by targeting the retinoid signaling pathway essential for spermatogenesis. | Feb 11 2026 |
| E6630 | NT-0527 | NT-0527 is a potent, specific, and brain-penetrant inhibitor of the NLRP3 inflammasome with oral bioavailability and demonstrated efficacy in an in vivo model of inflammation. | Feb 08 2026 |
| S8827 | Diprovocim | Diprovocim is a potent synthetic agonist that activates the human TLR1/TLR2 heterodimer with an EC50 of 110 pM in THP-1 cells. It also exhibits significant potential as an immune adjuvant. | Feb 04 2026 |
| E6670 | AC-4-130 | AC-4–130 is a potent, selective inhibitor of the STAT5 SH2 domain that directly binds to STAT5, blocking its phosphorylation, dimerization, and nuclear translocation. It acts by disrupting STAT5-dependent gene transcription, effectively reducing pathological STAT5 activity in acute myeloid leukemia (AML). | Feb 03 2026 |
| E6675 | MC3482 | MC3482 is a specific, cell-permeable inhibitor of SIRT5 that mitigates microglia-induced neuroinflammation and neuronal apoptosis by regulating Annexin-A1 succinylation. It significantly improves long-term sensorimotor and cognitive function, exhibiting potential for anti-ischemic stroke treatment. | Feb 03 2026 |
| E6509 | AR420626 | AR420626 is a selective agonist of FFAR3 (GPR41) with an IC50 of 117 nM, that prevents serotonin-induced circular muscle relaxation ex vivo and defecation in vivo. | Feb 03 2026 |
| E6626 | STAT3-IN-3 | STAT3-IN-3 is a potent, selective chemical inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that has shown efficacy in mitigating drug resistance. | Feb 03 2026 |
| E8326 | HNHA | HNHA (N-hydroxy-7-(2-naphthylthio) heptanomide) is a cell-permeable inhibitor of histone deacetylase (HDAC) activity, a key enzyme in gene expression and carcinogenesis with an IC50 of 100 nM. It also exhibits anti-tumor activity both in vitro and in vivo. | Feb 03 2026 |
| E6726 | N-Hydroxysuccinimide | N-Hydroxysuccinimide (HOSu; 1-Hydroxy-2,5-pyrrolidinedione) is a crucial reagent that forms NHS esters via DCC-mediated carboxylic acid activation. These esters enable covalent protein/antibody coupling to surfaces through primary amine reactions. It also modifies microfluidic SPR sensors for bacterial pathogen detection. | Feb 01 2026 |
| A2177 | Anti-mouse IFNγR (CD119)-Invivo | Anti-mouse IFNγR (CD119)-Invivo reacts with the mouse IFNγR (interferon gamma receptor) α chain also known as CD119 and IFNγ receptor 1. CD119 heterodimerizes with IFNγ receptor 2 (AF-1) to form the IFNγR, a Class II cytokine receptor. | Jan 26 2026 |
| A2178 | Anti-mouse/human IL-5-Invivo | Anti-mouse/human IL-5-Invivo reacts with mouse and human interleukin-5 (IL-5), a 26 kDa homodimeric cytokine. IL-5 stimulates B lymphocyte differentiation and proliferation and increases the secretion of IgM and IgA. | Jan 26 2026 |
| E1822 | Acoramidis hydrochloride | Acoramidis hydrochloride (AG10 hydrochloride) is an orally active, selective kinetic stabilizer of WT-transthyretin (TTR) and V122I mutant transthyretin (TTR), providing effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). | Jan 22 2026 |
| E6699 | Opiranserin hydrochloride | Opiranserin hydrochloride (VVZ-149 hydrochloride) is a non-opioid and non-NSAID analgesic that acts as a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50 of 0.86 μM and 1.3 μM, respectively. | Jan 22 2026 |
| S9883 | RMC-5552 | RMC-5552 is a selective bi-steric inhibitor of mTORC1, with the potential for treating mTORC1-activated tumors. It potently inhibits mTORC1-mediated phosphorylation of pS6K and p4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. | Jan 22 2026 |
| A2176 | Anti-mouse CD8α (53-6.7)-Invivo | Anti-mouse CD8α (53-6.7)-Invivo reacts with mouse CD8α. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). | Jan 20 2026 |
| E6671 | CMPD-39 | CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays. | Jan 19 2026 |
| E6515 | ML-60218 | ML-60218 is a broad-spectrum inhibitor of RNA polymerase III (pol III), with an IC50 of 32 μM for Saccharomyces cerevisiae and 27 μM for human pol III. ML-60218 disrupts pre-assembled viroplasms and impedes the formation of new ones, acting independently of de novo transcription of cellular RNAs. | Jan 19 2026 |
| F4016 | OGT Antibody [E11N9] | Jan 16 2026 | |
| F4050 | Phospho-AKT1 (Thr450) Antibody [H24E24] | Jan 16 2026 | |
| F4614 | RSK1 Antibody [P7B9] | Jan 16 2026 | |
| F4777 | GATA-4 Antibody [J18F23] | Jan 16 2026 | |
| F4828 | FGF2 Antibody [E17H24] | Jan 16 2026 | |
| F2613 | Phospho-TAK1 (Ser439) Antibody [F17C11] | Jan 16 2026 | |
| F3409 | POLDIP2 Antibody [N1K14] | Jan 16 2026 | |
| F0402 | Phospho-TAK1 (Thr184/187) Antibody [G4C5] | Jan 16 2026 | |
| F0396 | Phospho-HDAC4 (S246)/5 (S259)/7 (S155) Antibody [H5N6] | Jan 16 2026 | |
| F5127 | CNBP Antibody [E10D2] | Jan 16 2026 | |
| F4827 | JAK3 Antibody [M5G12] | Jan 16 2026 | |
| F4751 | Phospho-MEK1 (Ser298) Antibody [L22P14] | Jan 16 2026 | |
| F4738 | FXR1 Antibody [G5P16] | Jan 16 2026 | |
| F4918 | Phospho-Akt1 (Ser129) Antibody [K23C4] | Jan 16 2026 | |
| E6651 | HGC652 | HGC652 is a TRIM21-dependent molecular glue degrader that binds the E3 ubiquitin ligase TRIM21 (Kd ≈ 0.06 µM) to induce a TRIM21–NUP98 ternary complex, driving the ubiquitination and selective degradation of nuclear pore complex proteins like NUP155, leading to nuclear pore collapse and cancer cell death. | Jan 14 2026 |
| P1269 | Pegcetacoplan acetate | Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular hemolysis) and downstream MAC formation (intravascular hemolysis). | Jan 13 2026 |
| E8319 | Ro 48-8071 fumarate | Ro 48-8071 fumarate is a potent, selective inhibitor of 2,3-oxidosqualene cyclase (OSC) (IC50 = 6.5 nM), a key enzyme downstream of HMG-CoA reductase that catalyzes lanosterol formation in cholesterol biosynthesis. It reduces intracellular cholesterol levels without the feedback upregulation of HMG-CoA reductase seen with statins, providing a distinct, self-limiting regulatory loop for lowering LDL-C. Additionally, it also exhibits significant anti-cancer properties by inducing apoptosis and disrupting cell signaling in cancer models. | Jan 13 2026 |
| F3733 | Claudin18.2 Antibody [L24N19] | Claudin 18,Claudin18.2 | Jan 12 2026 |
| F3922 | Phospho-Tau (Ser262) Antibody [N15P23] | Jan 12 2026 | |
| F4944 | SCG10/Stathmin-2 Antibody [D11B18] | Jan 12 2026 | |
| F4375 | Na+/H+ Exchanger-1 Antibody [K9D3] | Jan 12 2026 | |
| F4810 | PEN2 Antibody [E13J21] | Jan 12 2026 | |
| F3707 | Na(+)/K(+)-transporting ATPase (pan α subunit) Antibody [G11K19] | ATP1A1/ATP1A2/ATP1A3/ATP1A4 | Jan 12 2026 |
| F4620 | MMP-3 Antibody [K11K15] | Jan 12 2026 | |
| F1630 | ABCA1 Antibody [D20K13] | ABC1,ABCA1 | Jan 12 2026 |
| F2603 | Wnt3 and Wnt3a Antibody [J20B9] | Jan 12 2026 | |
| E6564 | VG-3927 | VG‐3927 is a potent, selective, and brain-penetrant agonist of TREM2 that induces anti-inflammatory microglial activation and has the potential to treat Alzheimer's disease (AD). | Jan 12 2026 |
| F5002 | Integrin αV Antibody [P12L6] | Jan 12 2026 | |
| F1719 | MBP tag Antibody [E2A2] | Maltose Binding Protein,MBP tag,MBP-probe | Jan 12 2026 |
| F2110 | Otoferlin Antibody [J18F12] | Jan 12 2026 | |
| E8330 | NIC3 | NIC3 is a selective inhibitor of nucleus accumbens-associated protein 1 (NAC1), a BTB/POZ domain-containing transcription corepressor overexpressed in cancers. It binds the conserved Leu-90 residue in NAC1's BTB domain, disrupting homodimerization essential for nuclear body formation and stability. | Jan 05 2026 |
| E8325 | Quadrol | Quadrol (N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine, EDTP) is an immunostimulant which is considered as a potentially useful active molecule for accelerating wound healing. Quadrol can form a complex with Ca²⁺, mediate the entry of Ca²⁺ into macrophages, and stimulate macrophage activation. | Jan 05 2026 |
| E8327 | DHBS | DHBS (Sodium 3,5-dichloro-2-hydroxybenzenesulphonate) is used in conjunction with 4-aminoantipyrine (4-AAP) and hydrogen peroxide (H2O2) for chromogenic quantitation of uric acid in serum and urine samples. | Jan 05 2026 |
| E6635 | MC3138 | MC3138 is a selective activator of SIRT5 and inhibits proliferation in SIRT5-low PDAC cell lines and organoids by restoring SIRT5-mediated desuccinylation and deacetylation. | Jan 04 2026 |
| E0853 | 360A | 360A stabilizes G-quadruplex structures and inhibits telomerase activity, showing an IC50 of 300 nM in TRAP-G4 assays. | Dec 31 2025 |
| A2175 | Anti-mouse CD11c-Invivo | Anti-mouse CD11c-Invivo reacts with mouse CD11c, the most widely used defining marker for murine dendritic cells (DCs). CD11c is also known as integrin alpha-X (Itgax) and CD11 antigen-like family member C. | Dec 30 2025 |
| E6667 | JNJ-9350 | JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research. | Dec 24 2025 |
| E8329 | VQW-765 | VQW-765 (AQW-051) is an orally active agonist targeting the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), exhibiting a pKD of 7.56 for the human recombinant α7-nAChR. This compound demonstrates anxiolytic-like activity in animal models. VQW-765 has potential applications in anxiety disorder and acute performance anxiety studies. | Dec 24 2025 |
| E1789 | Asundexian | Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, asundexian exhibits an IC50 of 1 nM against human FXIa. | Dec 24 2025 |
| E6656 | STAT3-IN-13 | STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumor growth and metastasis. STAT3-IN-13 has potential applications in cancer research. | Dec 24 2025 |
| E5872 | BBO-10203 | BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research. | Dec 24 2025 |
| E8324 | GE11 | GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research. | Dec 21 2025 |
| E0850 | DPhPC | DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties. | Dec 14 2025 |
| F4429 | Uteroglobin/CC10 Antibody [H18P18] | Dec 12 2025 | |
| F4670 | Keratin 18 Antibody [M2J10] | Dec 12 2025 | |
| F4793 | IRF-9 Antibody [N16H20] | Dec 12 2025 | |
| F4438 | GPX1/2 Antibody [L20K22] | Dec 12 2025 | |
| F1291 | JAK3 Antibody [F8D8] | Dec 12 2025 | |
| F1643 | Glutathione Antibody [A11G7] | Dec 12 2025 | |
| F2030 | 5-hydroxymethylcytosine Antibody [B13H23] | Dec 12 2025 | |
| F2031 | VSV-G tag Antibody [N12B16] | VSV Glycoprotein,VSV-G tag | Dec 12 2025 |
| F2238 | Influenza A Virus M2 Protein Antibody [L21L24] | Influenza A M2,Influenza A Virus M2 Protein | Dec 12 2025 |
| F3018 | IFN-γ Antibody [A4P20] | IFN-γ,Interferon gamma | Dec 12 2025 |
| F3039 | Acetyl-CoA Carboxylase 2 Antibody [E20M20] | Dec 12 2025 | |
| F2353 | VEGFB Antibody [E11E24] | VEGFB,VEGF-B | Dec 12 2025 |
| F2701 | Thymine Dimer Antibody [E15K19] | Dec 12 2025 | |
| F2741 | uPA Antibody [F9E24] | uPA,Urokinase | Dec 12 2025 |
| F3241 | Phospho-β Catenin (Ser675) Antibody [D16B23] | Dec 12 2025 | |
| F3306 | Phospho-Nephrin (Tyr1217) Antibody [L5D2] | Dec 12 2025 | |
| F3647 | Phospho-EGFR (Tyr992) Antibody [F20E14] | EGFR (phospho Y992),Phospho-EGF Receptor (Tyr992) | Dec 12 2025 |
| F3783 | Phospho-JAK1 (Tyr1034 + Tyr1035) Antibody [F22D15] | JAK1 (phospho Y1034 + Y1035),Phospho-Jak1(Tyr1034/1035) | Dec 12 2025 |
| F4985 | Cleaved PARP (Asp214) Antibody [C3D4] | Dec 12 2025 | |
| F4192 | Caspase-1 Antibody [C2H20] | Dec 12 2025 | |
| F4203 | ATF-6 Antibody [G8H4] | Dec 12 2025 | |
| F4779 | Mannose Receptor Antibody [E13A19] | Dec 12 2025 | |
| F2860 | Phospho-TBK1/NAK (Ser172) Antibody [G18L12] | NAK/TBK1 (phospho S172),Phospho-TBK1/NAK (Ser172) | Dec 12 2025 |
| F4919 | Myc tag Antibody [A14H15] | Dec 12 2025 | |
| E8323 | Emeramide | Emeramide functions as a thiol-based redox antioxidant and chelates heavy metals. | Dec 10 2025 |
| E0848 | Pinealon | Pinealon is a tripeptide exhibiting neuroprotective effects. This peptide inhibits reactive oxygen species (ROS) buildup and blocks ERK 1/2 activation. It enhances functional activity of key brain tissue cellular components while decreasing spontaneous cell death rates. Studies demonstrate Pinealon's protective effects against prenatal hyperhomocysteinemia in rat offspring. | Dec 10 2025 |
| E6646 | BMS-986260 | BMS-986260 is an orally active immuno-oncology agent that inhibits TGFβR1 with an IC50 of 1.6 nM. It shows selectivity for TGFβR1 compared to TGFβR2 and over 200 other kinases. In MINK and NHLF cell lines, BMS-986260 blocks TGFβ-induced pSMAD2/3 nuclear translocation with IC50 values of 350 nM and 190 nM, respectively. | Dec 09 2025 |
| E6560 | naperiglipron | Naperiglipron (LY3549492) (Example 2) acts as a glucagon-like peptide 1 receptor (GLP-1R) agonist, exhibiting an EC50 of 1.14 nM at hGLP-1R. In GLP-1R knock-in mouse models, it reduces blood glucose levels. The compound shows PDE10A1 enzyme inhibitory activity (IC50: 7.43 μM) and displays weak hERG inhibition. Naperiglipron has potential applications in type II diabetes mellitus (T2DM) and obesity studies. | Dec 08 2025 |
| P1231 | Mazdutide (IBI362, LY330567) | Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D). | Dec 04 2025 |
| E6643 | SS-3091 | SS‑3091 is a potent inhibitor of pan‑KRas that targets the interaction interfaces of KRas, destabilizing critical KRas–protein complexes and thereby blocking its downstream signaling pathways. SS‑3091 effectively inhibits KRas‑driven signaling in multiple cancer cell lines, including those harboring G12D, G12V, and G13D mutations, leading to reduced ERK and AKT phosphorylation. | Dec 04 2025 |
| E5927 | Mito-LND (Mito-Lonidamine) | Mito-LND (Mito-Lonidamine) is a mitochondria-targeted derivative of lonidamine conjugated with a triphenylphosphonium cation that selectively accumulates in cancer cell mitochondria due to their high membrane potential. It potently inhibits oxidative phosphorylation (OXPHOS) by disrupting respiratory complexes I and II, stimulating ROS production and Prx3 oxidation while suppressing AKT/mTOR/p70S6K signaling. | Dec 04 2025 |
| E6511 | ADT-1004 | ADT-1004 is an orally bioavailable prodrug of ADT-007, that acts as a first-in-class selective inhibitor of pan-RAS with potent antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models. | Dec 04 2025 |
| E6647 | Bireociclib (XZP-3287,CDK4/6-IN-2) | CDK4/6-IN-2 is a CDK4 and CDK6 inhibitor obtained from patent US20180000819A1 (Compound 1). It exhibits IC50 values of 2.7 nM for CDK4 and 16 nM for CDK6. | Dec 04 2025 |
| E6517 | PKN1 | PKN1/2-IN-1 is a cell-permeable compound that inhibits PKN1 and PKN2, with IC50 values of 16 nM and 210 nM, and Ki values of 8 nM and 108 nM, respectively. In NanoBRET assays, it shows intracellular PKN2 binding with an IC50 of 2.1 μM. This compound is applicable for investigating tumor cell migration and related physiological processes. | Dec 02 2025 |
| E6521 | HRS‑5346 | Lp(a)-IN-5 (Compound A) is an orally administered lipoprotein(a) (Lp(a)) inhibitor. This compound demonstrates inhibition of Apo(a) and ApoB protein assembly with an IC50 of 0.41 nM. It may be useful for studying diseases associated with increased plasma Lp(a) levels, including cardiovascular disorders. | Dec 02 2025 |
| E6578 | AS1708727 | AS1708727 is an orally bioavailable Foxo1 inhibitor that exhibits EC50 values of 0.33 μM against G6Pase and 0.59 μM against PEPCK. | Dec 02 2025 |
| E6498 | Atebimetinib (IMM-1-104) | Atebimetinib inhibits MEK tyrosine kinase and demonstrates antineoplastic effects. | Dec 02 2025 |
| E6636 | DY268 | DY268 is a farnesoid X receptor (FXR) antagonist with an IC50 of 7.5 nM. In cellular assays, it inhibits FXR transactivation with an IC50 of 468 nM. This compound has applications in drug-induced liver injury (DILI) research. | Nov 25 2025 |
| E6634 | Thiethylperazine | Thiethylperazine is a phenothiazine derivative that acts as an oral dopamine D2-receptor and histamine H1-receptor antagonist. This compound functions as an ABCC1 activator and has been shown to decrease amyloid-β (Aβ) accumulation in mice. It exhibits anti-emetic, antipsychotic, and antimicrobial properties. | Nov 25 2025 |
| E6565 | Ofirnoflastum | Ofirnoflast (Ofirnoflastum) inhibits serine/threonine-protein kinase Nek7 and exhibits anti-inflammatory activity. | Nov 24 2025 |
| E6572 | AD1058 | AD1058 is an orally bioavailable ATR inhibitor with blood-brain barrier permeability (IC50 = 1.6 nM). It demonstrates antitumor effects through inhibition of tumor cell proliferation, induction of cell cycle arrest, and promotion of apoptosis. This compound is applicable for studies involving advanced malignancies and brain metastases. | Nov 24 2025 |
| E6588 | LY3509754 | LY3509754 (IL-17A inhibitor 1) inhibits IL-17A, showing IC50 values of <9.45 nM in alphalisa assay and 9.3 nM in HT-29 cells. | Nov 24 2025 |
| E1892 | FM4-64 | FM4-64 is a very lipophilic, water-soluble styryl dye that specifically binds to cell membranes and inner membrane organelles to produce fluorescence upon insertion into lipid bilayers. It is widely used as a marker for endocytic and exocytic membrane structures, tracking vesicle trafficking in live cells with minimal aqueous background fluorescence. | Nov 21 2025 |
| E1162 | GLPG0974 | GLPG0974 is a potent and selective antagonist of the human free fatty acid receptor 2 (FFA2/GPR43) with an IC50 of 9 nM and also inhibits SCFA‐induced neutrophil activation and migration. | Nov 21 2025 |
| E4757 | Setidegrasib (ASP3082) | ASP3082 (Setidegrasib; KRAS G12D inhibitor 17) is a PROTAC degrader targeting KRAS(G12D) with a DC50 of 38 nM. It effectively inhibits growth in various KRAS(G12D)-mutated cancer cell lines, including pancreatic (PK-59, HPAC) and colorectal (GP2d, GP5d) with IC50 values ranging from 3.6 to 29 nM. | Nov 20 2025 |
| E2989 | AZD5904 | AZD5904 is a selective and irreversible human Myeloperoxidase (MPO) inhibitor. AZD5904 reduces 3-chlorotyrosine-modified MYBPC3 levels, restores MYBPC3 phosphorylation, and alleviates the calcium signalling and relaxation defects. | Nov 20 2025 |
| E5946 | C12FDG | C12FDG (5-Dodecanoylaminofluorescein di-β-D-galactopyranoside) is a lipophilic green fluorescent probe used to detect β-galactosidase activity. C12FDG demonstrates greater sensitivity for measuring β-galactosidase activity in animal cells than fluorescein di(β-D-galactopyranoside). | Nov 20 2025 |
| E6600 | 3FAx-Neu5Ac | 3Fax-Neu5Ac is a fluorinated sialic acid analogue that inhibits sialyltransferase activity, reduces cellular sialylation, and leads to decreased MHC expression and suppression of myoblast fusion, thereby demonstrating potential in regulating skeletal muscle cell differentiation. | Nov 20 2025 |
| E6603 | USP5-IN-1 | USP5‑IN‑1 (compound 64) is a selective, competitive inhibitor of the USP5 zinc finger ubiquitin‑binding domain (ZnF‑UBD) with a KD of 2.8 μM. It also suppresses USP5 catalytic activity and inhibits the hydrolysis of unanchored ubiquitin chains. | Nov 20 2025 |
| E6614 | FABPs ligand 6 (MF6) | FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS). | Nov 20 2025 |
| E6610 | GPX4-IN-5 | GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research. | Nov 20 2025 |
| E1154 | DS18561882 | DS18561882 is a potent, tricyclic coumarin-based inhibitor of MTHFD2 with an IC50 of 0.0063 μM, exhibiting significant selectivity over the cytosolic isozyme MTHFD1. It also effectively inhibits tumor growth in mouse xenograft models in vivo. | Nov 20 2025 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.